Company: PTHS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001753926-25-001764
Chunk: 1

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
 long-term liabilities 
     26,175  
     — 

    Total liabilities 
     68,180  
     4,083 

    Commitments and contingencies (Note 11) 
     —  

    STOCKHOLDERS’ EQUITY (DEFICIT) 

    Preferred stock Series A, $0.0001 par value, 150,000 shares authorized, 57,568 shares issued and outstanding as of September 30, 2025 and 700,000 shares authorized, no shares issued or outstanding as of December 31, 2024, respectively 
     —  
     — 

    Preferred stock Series C, $0.0001 par value, 5,000 shares authorized, 2,600 and 2,600 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 
     —  
     — 

    Common stock, $0.0001 par value, 200,000,000 shares authorized, 3,090,729 and 610,389 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 
     —  
     — 

    Additional paid in capital 
     101,383  
     18,761 

    Accumulated deficit 
     (43,130) 
     (21,475)

    Total stockholders’ equity (deficit) 
     58,253  
     (2,714)

    Total liabilities and stockholders’ equity (deficit) 
    $126,433  
    $1,369 

The
accompanying notes are an integral part of these condensed consolidated financial statements.

2

PELTHOS
THERAPEUTICS INC.  

CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS 

FOR
THE THREE AND NINE MONTHS
ENDED SEPTEMBER 30, 2025 AND 2024 

(Unaudited) 

(in
thousands, except share and per share amounts)

    For the Three months Ended September 30,  
    For the Nine months Ended September 30, 

    2025  
    2024  
    2025  
    2024 

    Revenue 

    Net product revenues 
    $